Share Price and Basic Stock Data
Last Updated: December 26, 2025, 11:21 pm
| PEG Ratio | -2.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Evoq Remedies Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹9.04 Cr and a share price of ₹3.63. The company reported a significant dip in revenue in recent quarters, with sales figures standing at ₹4.60 Cr in March 2023 and declining further to ₹3.90 Cr by September 2023. This downward trend is notable when considering the peak sales of ₹15.79 Cr achieved in September 2022, reflecting a volatility in revenue generation. The trailing twelve months (TTM) revenue reached ₹37.27 Cr, indicating a potential for recovery, particularly with the upcoming projected sales of ₹11.76 Cr for March 2025. The company’s operating profit margin (OPM) has also fluctuated, with a negative OPM of -5.10% reported for March 2025, highlighting challenges in managing operational costs effectively. This inconsistency in revenue and margins underscores a need for strategic adjustments to stabilize performance moving forward.
Profitability and Efficiency Metrics
The profitability metrics for Evoq Remedies Ltd reveal a concerning trend, particularly in operating profit which recorded a loss of ₹4.04 Cr in March 2023 and further declined to -₹1.72 Cr in March 2024. The operating profit margin (OPM) reflected this downturn with a striking -87.83% in March 2023 and a continued negative margin thereafter. The net profit for the latest fiscal year stood at ₹1.76 Cr, with an earnings per share (EPS) of ₹0.04 for March 2025, significantly lower than the ₹1.19 EPS reported in March 2023. The cash conversion cycle (CCC) was recorded at 231.85 days, indicative of inefficiencies in managing working capital, which could potentially strain liquidity. Overall, the company’s return on equity (ROE) was a modest 0.26%, suggesting that shareholder equity is not being effectively utilized to generate profits.
Balance Sheet Strength and Financial Ratios
Evoq Remedies Ltd’s balance sheet presents a picture of limited leverage, as evidenced by zero borrowings reported across the latest periods, which is a strength in managing debt. The company’s reserves stood at ₹19.69 Cr, providing a cushion for operational challenges. However, the financial ratios indicate mixed performance; the price-to-book value (P/BV) ratio was low at 0.14x, suggesting that the stock may be undervalued relative to its book value. The interest coverage ratio (ICR) of 0.00x further highlights the company’s inability to cover interest expenses, although no interest expenses have been recorded in recent years. The current ratio of 9.10x indicates strong liquidity, allowing the company to meet short-term obligations comfortably. However, the return on capital employed (ROCE) was only 0.35%, reflecting inefficiencies in generating returns on invested capital.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Evoq Remedies Ltd has undergone significant changes, particularly with promoter holdings decreasing from 73.53% in March 2022 to 11.21% by March 2025. This reduction raises concerns regarding management control and may affect investor confidence. The public holding has conversely increased from 26.47% in March 2022 to 88.79% by March 2025, indicating a shift toward a more retail investor base. The number of shareholders also rose to 1,679, reflecting growing interest in the stock despite its recent performance challenges. The lack of institutional investor participation (FIIs and DIIs reported as N/A) could be a red flag, as institutional backing is often seen as a vote of confidence in a company’s future prospects. The current distribution suggests a need for the company to engage with institutional investors to bolster credibility and stability.
Outlook, Risks, and Final Insight
The outlook for Evoq Remedies Ltd is contingent on its ability to stabilize sales and improve operational efficiency in the coming quarters. The company faces several risks, including fluctuating revenue and declining profitability metrics that could deter potential investors. Additionally, maintaining liquidity while addressing operational challenges will be crucial. If the company can successfully navigate these issues, it may experience a resurgence in sales, particularly with the projected figures for March 2025. Conversely, failure to improve operational metrics and manage working capital effectively could lead to further declines in profitability and investor confidence. The ongoing changes in shareholding dynamics, particularly the significant reduction in promoter stakes, may also pose a challenge in restoring investor trust. Overall, strategic initiatives focused on operational improvements and stakeholder engagement will be essential for the company’s recovery and growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 443 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,100.18 Cr | 1,149.90 | 52.73 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 4.93 | 11.85 | 15.79 | 4.60 | 3.90 | 0.15 | 0.00 | 11.76 | 25.51 |
| Expenses | 1.71 | 4.20 | 11.12 | 15.48 | 8.64 | 3.83 | 1.87 | 1.63 | 12.36 | 26.46 |
| Operating Profit | 1.05 | 0.73 | 0.73 | 0.31 | -4.04 | 0.07 | -1.72 | -1.63 | -0.60 | -0.95 |
| OPM % | 38.04% | 14.81% | 6.16% | 1.96% | -87.83% | 1.79% | -1,146.67% | -5.10% | -3.72% | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 0.00 | 2.26 | 0.01 | 2.40 | 1.06 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Profit before tax | 1.05 | 0.73 | 0.73 | 0.31 | 1.98 | 0.07 | 0.54 | -1.62 | 1.76 | 0.08 |
| Tax % | 22.86% | 0.00% | 50.68% | 0.00% | 33.84% | 28.57% | 29.63% | 0.00% | 2.27% | 25.00% |
| Net Profit | 0.81 | 0.73 | 0.36 | 0.31 | 1.31 | 0.05 | 0.38 | -1.62 | 1.71 | 0.05 |
| EPS in Rs | 810.00 | 730.00 | 0.26 | 0.23 | 0.96 | 0.04 | 0.28 | -0.65 | 0.69 | 0.02 |
Last Updated: December 27, 2025, 1:04 am
Below is a detailed analysis of the quarterly data for Evoq Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 25.51 Cr.. The value appears strong and on an upward trend. It has increased from 11.76 Cr. (Mar 2025) to 25.51 Cr., marking an increase of 13.75 Cr..
- For Expenses, as of Sep 2025, the value is 26.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.36 Cr. (Mar 2025) to 26.46 Cr., marking an increase of 14.10 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.95 Cr.. The value appears to be declining and may need further review. It has decreased from -0.60 Cr. (Mar 2025) to -0.95 Cr., marking a decrease of 0.35 Cr..
- For OPM %, as of Sep 2025, the value is -3.72%. The value appears strong and on an upward trend. It has increased from -5.10% (Mar 2025) to -3.72%, marking an increase of 1.38%.
- For Other Income, as of Sep 2025, the value is 1.06 Cr.. The value appears to be declining and may need further review. It has decreased from 2.40 Cr. (Mar 2025) to 1.06 Cr., marking a decrease of 1.34 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.04 Cr. (Mar 2025) to 0.03 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 1.76 Cr. (Mar 2025) to 0.08 Cr., marking a decrease of 1.68 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 2.27% (Mar 2025) to 25.00%, marking an increase of 22.73%.
- For Net Profit, as of Sep 2025, the value is 0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 1.71 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 1.66 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.02. The value appears to be declining and may need further review. It has decreased from 0.69 (Mar 2025) to 0.02, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:23 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.25 | 9.07 | 10.02 | 16.78 | 20.39 | 4.05 | 11.76 | 37.27 |
| Expenses | 3.23 | 9.07 | 9.07 | 15.32 | 24.12 | 5.69 | 13.99 | 38.82 |
| Operating Profit | 0.02 | 0.00 | 0.95 | 1.46 | -3.73 | -1.64 | -2.23 | -1.55 |
| OPM % | 0.62% | 0.00% | 9.48% | 8.70% | -18.29% | -40.49% | -18.96% | -4.16% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 6.02 | 2.26 | 2.41 | 3.46 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.07 |
| Profit before tax | 0.02 | 0.00 | 0.95 | 1.46 | 2.29 | 0.61 | 0.13 | 1.84 |
| Tax % | 0.00% | 25.26% | 25.34% | 29.26% | 26.23% | 30.77% | ||
| Net Profit | 0.01 | 0.00 | 0.72 | 1.09 | 1.62 | 0.45 | 0.09 | 1.76 |
| EPS in Rs | 10.00 | 0.00 | 720.00 | 0.80 | 1.19 | 0.33 | 0.04 | 0.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | 51.39% | 48.62% | -72.22% | -80.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 151.39% | -2.77% | -120.85% | -7.78% |
Evoq Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -11% |
| TTM: | 190% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -56% |
| TTM: | -80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -43% |
| 1 Year: | -60% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:51 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 13.60 | 13.60 | 13.60 | 24.90 | 24.90 |
| Reserves | 0.01 | 0.01 | 0.73 | 9.57 | 11.19 | 11.64 | 19.64 | 19.69 |
| Borrowings | 0.00 | 0.01 | 0.00 | 8.16 | 9.58 | 4.24 | 0.00 | 0.00 |
| Other Liabilities | 2.12 | 5.62 | 7.30 | 2.00 | 0.53 | 7.39 | 5.47 | 7.63 |
| Total Liabilities | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 52.22 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.22 | 0.20 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.89 | 36.86 | 49.79 | 52.02 |
| Total Assets | 2.14 | 5.65 | 8.04 | 33.33 | 34.90 | 36.87 | 50.01 | 52.22 |
Below is a detailed analysis of the balance sheet data for Evoq Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.90 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.90 Cr..
- For Reserves, as of Sep 2025, the value is 19.69 Cr.. The value appears strong and on an upward trend. It has increased from 19.64 Cr. (Mar 2025) to 19.69 Cr., marking an increase of 0.05 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.63 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.47 Cr. (Mar 2025) to 7.63 Cr., marking an increase of 2.16 Cr..
- For Total Liabilities, as of Sep 2025, the value is 52.22 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 50.01 Cr. (Mar 2025) to 52.22 Cr., marking an increase of 2.21 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.22 Cr. (Mar 2025) to 0.20 Cr., marking a decrease of 0.02 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 52.02 Cr.. The value appears strong and on an upward trend. It has increased from 49.79 Cr. (Mar 2025) to 52.02 Cr., marking an increase of 2.23 Cr..
- For Total Assets, as of Sep 2025, the value is 52.22 Cr.. The value appears strong and on an upward trend. It has increased from 50.01 Cr. (Mar 2025) to 52.22 Cr., marking an increase of 2.21 Cr..
Notably, the Reserves (19.69 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.02 | -0.01 | 0.95 | -6.70 | -13.31 | -5.88 | -2.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 138.14 | 189.94 | 249.16 | 552.50 | 308.25 | 156.81 | 267.54 |
| Inventory Days | 3.39 | 2.42 | 6.97 | 20.66 | 38.33 | 732.34 | 61.90 |
| Days Payable | 239.57 | 226.66 | 315.25 | 32.05 | -10.20 | 767.44 | 97.59 |
| Cash Conversion Cycle | -98.04 | -34.30 | -59.11 | 541.11 | 356.78 | 121.72 | 231.85 |
| Working Capital Days | 1.12 | 1.21 | 26.23 | 436.56 | 440.90 | 2,263.00 | 1,369.06 |
| ROCE % | 0.00% | 246.75% | 9.11% | 6.97% | 1.91% | 0.35% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
| Diluted EPS (Rs.) | 0.04 | 0.03 | 1.19 | 1.09 | 10.05 |
| Cash EPS (Rs.) | 0.05 | 0.33 | 1.19 | 0.80 | 713.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 17.89 | 18.56 | 18.22 | 17.03 | 736.40 |
| Revenue From Operations / Share (Rs.) | 4.72 | 2.98 | 14.99 | 12.34 | 10024.80 |
| PBDIT / Share (Rs.) | 0.07 | 0.45 | 1.68 | 1.08 | 953.90 |
| PBIT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.08 | 953.90 |
| PBT / Share (Rs.) | 0.05 | 0.44 | 1.68 | 1.07 | 953.90 |
| Net Profit / Share (Rs.) | 0.03 | 0.33 | 1.19 | 0.80 | 713.80 |
| PBDIT Margin (%) | 1.50 | 15.26 | 11.22 | 8.71 | 9.51 |
| PBIT Margin (%) | 1.09 | 15.08 | 11.21 | 8.71 | 9.51 |
| PBT Margin (%) | 1.09 | 15.08 | 11.20 | 8.68 | 9.51 |
| Net Profit Margin (%) | 0.75 | 11.16 | 7.94 | 6.50 | 7.12 |
| Return on Networth / Equity (%) | 0.19 | 1.79 | 6.53 | 4.71 | 96.93 |
| Return on Capital Employeed (%) | 0.28 | 2.42 | 9.22 | 6.31 | 128.45 |
| Return On Assets (%) | 0.17 | 1.22 | 4.64 | 3.27 | 8.87 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.16 | 0.38 | 0.35 | 0.01 |
| Asset Turnover Ratio (%) | 0.27 | 0.11 | 0.59 | 0.81 | 1.46 |
| Current Ratio (X) | 9.10 | 3.17 | 3.45 | 3.28 | 1.10 |
| Quick Ratio (X) | 8.69 | 2.90 | 3.25 | 3.20 | 1.08 |
| Inventory Turnover Ratio (X) | 4.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 1761.31 | 316.78 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 1246.62 | 237.30 | 0.00 |
| Enterprise Value (Cr.) | 6.16 | 15.91 | 27.09 | 35.80 | 0.00 |
| EV / Net Operating Revenue (X) | 0.52 | 3.92 | 1.33 | 2.13 | 0.00 |
| EV / EBITDA (X) | 34.78 | 25.71 | 11.83 | 24.47 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
| Price / BV (X) | 0.14 | 0.46 | 0.71 | 1.33 | 0.00 |
| Price / Net Operating Revenue (X) | 0.54 | 2.91 | 0.86 | 1.83 | 0.00 |
| EarningsYield | 0.01 | 0.03 | 0.09 | 0.03 | 0.00 |
After reviewing the key financial ratios for Evoq Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 3. It has decreased from 0.33 (Mar 24) to 0.05, marking a decrease of 0.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.89. It has decreased from 18.56 (Mar 24) to 17.89, marking a decrease of 0.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.72. It has increased from 2.98 (Mar 24) to 4.72, marking an increase of 1.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.07, marking a decrease of 0.38.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.05, marking a decrease of 0.39.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.33 (Mar 24) to 0.03, marking a decrease of 0.30.
- For PBDIT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has decreased from 15.26 (Mar 24) to 1.50, marking a decrease of 13.76.
- For PBIT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For PBT Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 10. It has decreased from 15.08 (Mar 24) to 1.09, marking a decrease of 13.99.
- For Net Profit Margin (%), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 5. It has decreased from 11.16 (Mar 24) to 0.75, marking a decrease of 10.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 15. It has decreased from 1.79 (Mar 24) to 0.19, marking a decrease of 1.60.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 10. It has decreased from 2.42 (Mar 24) to 0.28, marking a decrease of 2.14.
- For Return On Assets (%), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 5. It has decreased from 1.22 (Mar 24) to 0.17, marking a decrease of 1.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. It has increased from 0.11 (Mar 24) to 0.27, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 9.10. This value exceeds the healthy maximum of 3. It has increased from 3.17 (Mar 24) to 9.10, marking an increase of 5.93.
- For Quick Ratio (X), as of Mar 25, the value is 8.69. This value exceeds the healthy maximum of 2. It has increased from 2.90 (Mar 24) to 8.69, marking an increase of 5.79.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 4.40, marking an increase of 4.40.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.16. It has decreased from 15.91 (Mar 24) to 6.16, marking a decrease of 9.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 1. It has decreased from 3.92 (Mar 24) to 0.52, marking a decrease of 3.40.
- For EV / EBITDA (X), as of Mar 25, the value is 34.78. This value exceeds the healthy maximum of 15. It has increased from 25.71 (Mar 24) to 34.78, marking an increase of 9.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For Price / BV (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 1. It has decreased from 0.46 (Mar 24) to 0.14, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 2.91 (Mar 24) to 0.54, marking a decrease of 2.37.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Evoq Remedies Ltd:
- Net Profit Margin: 0.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.28% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 8.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 5.24 (Industry average Stock P/E: 52.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1106, Empire Business Hub, Ahmedabad Gujarat 380060 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhumishth Patel | Managing Director |
| Mr. Narendrakumar Patel | Non Executive Director |
| Mr. Harsh Kothari | Independent Director |
| Ms. Pushpa Joshi | Independent Director |
FAQ
What is the intrinsic value of Evoq Remedies Ltd?
Evoq Remedies Ltd's intrinsic value (as of 26 December 2025) is 0.20 which is 94.59% lower the current market price of 3.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 9.21 Cr. market cap, FY2025-2026 high/low of 8.28/2.11, reserves of ₹19.69 Cr, and liabilities of 52.22 Cr.
What is the Market Cap of Evoq Remedies Ltd?
The Market Cap of Evoq Remedies Ltd is 9.21 Cr..
What is the current Stock Price of Evoq Remedies Ltd as on 26 December 2025?
The current stock price of Evoq Remedies Ltd as on 26 December 2025 is 3.70.
What is the High / Low of Evoq Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Evoq Remedies Ltd stocks is 8.28/2.11.
What is the Stock P/E of Evoq Remedies Ltd?
The Stock P/E of Evoq Remedies Ltd is 5.24.
What is the Book Value of Evoq Remedies Ltd?
The Book Value of Evoq Remedies Ltd is 17.9.
What is the Dividend Yield of Evoq Remedies Ltd?
The Dividend Yield of Evoq Remedies Ltd is 0.00 %.
What is the ROCE of Evoq Remedies Ltd?
The ROCE of Evoq Remedies Ltd is 0.35 %.
What is the ROE of Evoq Remedies Ltd?
The ROE of Evoq Remedies Ltd is 0.26 %.
What is the Face Value of Evoq Remedies Ltd?
The Face Value of Evoq Remedies Ltd is 10.0.